UK markets closed

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
33.05-0.23 (-0.69%)
At close: 04:00PM EDT
33.05 0.00 (0.00%)
After hours: 05:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 3.52B
Enterprise value 3.19B
Trailing P/E 478.56
Forward P/E 111.11
PEG ratio (5-yr expected) N/A
Price/sales (ttm)13.98
Price/book (mrq)7.76
Enterprise value/revenue 12.75
Enterprise value/EBITDA -21.35

Trading information

Stock price history

Beta (5Y monthly) 1.41
52-week change 3-46.44%
S&P500 52-week change 3-16.62%
52-week high 384.83
52-week low 326.81
50-day moving average 340.04
200-day moving average 344.02

Share statistics

Avg vol (3-month) 3775.07k
Avg vol (10-day) 3853.2k
Shares outstanding 5105.85M
Implied shares outstanding 6N/A
Float 8103.07M
% held by insiders 12.56%
% held by institutions 169.54%
Shares short (14 Sept 2022) 44.26M
Short ratio (14 Sept 2022) 45.93
Short % of float (14 Sept 2022) 44.70%
Short % of shares outstanding (14 Sept 2022) 44.02%
Shares short (prior month 14 Aug 2022) 44.37M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 316 Nov 2011

Financial highlights

Fiscal year

Fiscal year ends 29 Sept 2021
Most-recent quarter (mrq)29 Jun 2022

Profitability

Profit margin -61.58%
Operating margin (ttm)-63.84%

Management effectiveness

Return on assets (ttm)-13.41%
Return on equity (ttm)-33.79%

Income statement

Revenue (ttm)249.94M
Revenue per share (ttm)2.38
Quarterly revenue growth (yoy)-29.40%
Gross profit (ttm)138.29M
EBITDA -149.3M
Net income avi to common (ttm)-153.93M
Diluted EPS (ttm)-1.08
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)416.5M
Total cash per share (mrq)3.93
Total debt (mrq)81.11M
Total debt/equity (mrq)17.11
Current ratio (mrq)3.37
Book value per share (mrq)4.29

Cash flow statement

Operating cash flow (ttm)-91.58M
Levered free cash flow (ttm)-66.47M